Fierce Drug Development & Delivery Day

Free Virtual Event

‍

This program brings together leaders across biotech, pharma, and the broader development ecosystem to share practical, real-world strategies for keeping complex pipelines moving in today’s challenging funding and operating environment.

Serán's CEO, Dan Smithey, and industry veteran, Kurt Nielsen sit down for an insider CEO interview on Changing Landscape of Drug Development for Complex Molecules. The delivery of advanced medicines like oral GLP-1s represents a significant shift in the pharmaceutical landscape, moving beyond the traditional "rule of five" toward complex molecules. These therapies, which include peptides and PROTACs, present unique engineering hurdles that require an integrated approach to drug product design.

With increasing pressure to hit milestones, generate high-quality data, and make the right decisions early, teams are being asked to move faster and operate more efficiently than ever before. Throughout the day, we’ll explore what it truly takes to advance both small and large molecule programs—from turning discovery into clinical assets and scaling manufacturing, to managing risk, timelines, partnerships, and execution.

Register Here

‍